Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $1.02 Million - $1.33 Million
-3,615 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$259.0 - $414.71 $41,440 - $66,353
-160 Reduced 4.24%
3,615 $1.25 Million
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $60,008 - $70,303
-247 Reduced 6.14%
3,775 $1.06 Million
Q4 2020

Mar 04, 2021

BUY
$236.26 - $355.63 $16,538 - $24,894
70 Added 1.77%
4,022 $985,000
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $77,577 - $89,573
-293 Reduced 6.9%
3,952 $1.12 Million
Q2 2020

Jul 23, 2020

BUY
$258.66 - $342.55 $8,794 - $11,646
34 Added 0.81%
4,245 $1.14 Million
Q1 2020

Apr 23, 2020

SELL
$268.85 - $341.04 $111,841 - $141,872
-416 Reduced 8.99%
4,211 $1.27 Million
Q4 2019

Jan 21, 2020

SELL
$220.06 - $304.07 $28,607 - $39,529
-130 Reduced 2.73%
4,627 $1.37 Million
Q3 2019

Oct 16, 2019

BUY
$217.44 - $243.88 $78,713 - $88,284
362 Added 8.24%
4,757 $1.11 Million
Q2 2019

Aug 07, 2019

BUY
$219.29 - $241.72 $214,465 - $236,402
978 Added 28.62%
4,395 $1.03 Million
Q1 2019

Apr 23, 2019

SELL
$216.71 - $338.96 $101,853 - $159,311
-470 Reduced 12.09%
3,417 $807,000
Q4 2018

Feb 08, 2019

BUY
$278.5 - $352.75 $54,029 - $68,433
194 Added 5.25%
3,887 $1.16 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $161,430 - $211,106
550 Added 17.5%
3,693 $1.31 Million
Q2 2018

Aug 24, 2018

SELL
$257.52 - $306.91 $170 Million - $203 Million
-662,070 Reduced 99.53%
3,143 $912,000
Q2 2018

Aug 23, 2018

BUY
$257.52 - $306.91 $171 Million - $203 Million
662,120 Added 21407.05%
665,213 $2.54 Million
Q1 2018

May 10, 2018

BUY
$260.13 - $367.91 $170,125 - $240,613
654 Added 26.81%
3,093 $846,000
Q4 2017

Mar 28, 2018

BUY
$307.64 - $344.58 $750,333 - $840,430
2,439
2,439 $777,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $23B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mainstay Capital Management LLC Portfolio

Follow Mainstay Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mainstay Capital Management LLC , based on Form 13F filings with the SEC.

News

Stay updated on Mainstay Capital Management LLC with notifications on news.